Lopinavir News and Research

RSS

Antiretroviral drug Lopinavir selectively kills HPV-infected cells in lab tests

The protease inhibitor lopinavir - the primary component of Abbott Laboratories' antiretroviral drug Kaletra - selectively killed the human papillomavirus in laboratory tests, according to a study scheduled to be published next month in the journal Anti-Viral Therapy.

From The University of Manchester 30 Aug 2006

Simpler and less expensive method of controlling the progression of HIV

There might be a simpler and less expensive method of controlling the progression of HIV, according to several preliminary studies presented last Thursday at the XVI International AIDS Conference in Toronto, the Los Angeles Times reports (Chong, Los Angeles Times, 8/18).

20 Aug 2006

Importance of the drug Fuzeon (enfuvirtide) in the management of HIV

New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients.

20 Oct 2005

HIV/AIDS drugs may also be effective against malaria

Researchers at The Queensland Institute of Medical Research (QIMR) have found that drugs used to treat HIV Aids may also be effective against the biggest killer in the world - malaria.

2 Jun 2005

Widely used antimalarial drug exhibits antiviral activity against the SARS

Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.

5 Sep 2004

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV in patients who had failed prior PI-containing regimens, according to information presented at the International AIDS Conference (IAC).

12 Jul 2004